Compare Stocks: VYGR, CGEN, AGEN, and DTIL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$6.51 +1.7%	$7.70	$2.71 ▼ $10.31	$289.04M	1.31	1.11 million shs	553,852 shs
CGEN Compugen	$1.96 -7.5%	$2.38	$1.43 ▼ $3.23	$200.45M	2.78	208,493 shs	285,493 shs
DTIL Precision BioSciences	$6.78 +1.0%	$7.02	$3.53 ▼ $9.62	$185.21M	1.27	247,661 shs	132,428 shs
VYGR Voyager Therapeutics	$1.86 -7.9%	$2.90	$1.75 ▼ $5.48	$124.47M	1.28	885,094 shs	1.30 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	-0.31%	-1.54%	-23.17%	+3.39%	+49.18%
CGEN Compugen	-0.93%	+6.00%	-12.76%	-9.40%	+20.45%
DTIL Precision BioSciences	+2.29%	+11.28%	+3.23%	-8.46%	-4.01%
VYGR Voyager Therapeutics	-7.76%	+0.50%	-34.42%	-34.63%	-59.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGEN Agenus	$6.51 +1.7%	$7.70	$2.71 ▼ $10.31	$289.04M	1.31	1.11 million shs	553,852 shs
CGEN Compugen	$1.96 -7.5%	$2.38	$1.43 ▼ $3.23	$200.45M	2.78	208,493 shs	285,493 shs
DTIL Precision BioSciences	$6.78 +1.0%	$7.02	$3.53 ▼ $9.62	$185.21M	1.27	247,661 shs	132,428 shs
VYGR Voyager Therapeutics	$1.86 -7.9%	$2.90	$1.75 ▼ $5.48	$124.47M	1.28	885,094 shs	1.30 million shs

The 7 Best High-Yield Dividend Stocks for 2027

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGEN Agenus	-0.31%	-1.54%	-23.17%	+3.39%	+49.18%
CGEN Compugen	-0.93%	+6.00%	-12.76%	-9.40%	+20.45%
DTIL Precision BioSciences	+2.29%	+11.28%	+3.23%	-8.46%	-4.01%
VYGR Voyager Therapeutics	-7.76%	+0.50%	-34.42%	-34.63%	-59.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGEN Agenus	2.50	Moderate Buy	$24.50	276.34% Upside
CGEN Compugen	3.00	Buy	$5.00	155.10% Upside
DTIL Precision BioSciences	2.60	Moderate Buy	$32.25	375.66% Upside
VYGR Voyager Therapeutics	2.75	Moderate Buy	$16.50	787.10% Upside

Current Analyst Ratings Breakdown

Latest VYGR, CGEN, AGEN, and DTIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/22/2026	AGEN Agenus	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/12/2026	CGEN Compugen	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$4.00
10/9/2026	VYGR Voyager Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/8/2026	AGEN Agenus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (D) ➝ Sell (D+)
10/5/2026	AGEN Agenus	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$40.00
9/28/2026	AGEN Agenus	Rodman & Renshaw Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$19.00
9/18/2026	AGEN Agenus	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$40.00
8/27/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/21/2026	AGEN Agenus	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)
8/11/2026	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$30.00 ➝ $25.00
8/10/2026	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy

(Data available from 10/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGEN Agenus	$114.20M	2.57	N/A	N/A	($8.17) per share	-0.80
CGEN Compugen	$72.76M	2.55	$0.35 per share	5.67	$1.09 per share	1.80
DTIL Precision BioSciences	$34.26M	5.46	N/A	N/A	$4.03 per share	1.68
VYGR Voyager Therapeutics	$40.37M	2.84	N/A	N/A	$3.53 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGEN Agenus	$120K	$2.58	2.52	N/A	N/A	69.33%	-47.68%	57.73%	11/9/2026 (Estimated)
CGEN Compugen	$35.34M	$0.38	5.16	N/A	N/A	47.56%	42.57%	26.13%	11/9/2026 (Estimated)
DTIL Precision BioSciences	-$45.72M	-$2.80	N/A	N/A	N/A	-96.73%	-72.52%	-32.25%	11/2/2026 (Estimated)
VYGR Voyager Therapeutics	-$119.72M	-$1.80	N/A	N/A	N/A	-312.63%	-57.92%	-45.00%	11/9/2026 (Estimated)

Latest VYGR, CGEN, AGEN, and DTIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	AGEN Agenus	$0.02	N/A	N/A	N/A	$28.20 million	N/A
11/9/2026	Q3 2026	CGEN Compugen	-$0.08	N/A	N/A	N/A	$1.29 million	N/A
11/9/2026	Q3 2026	VYGR Voyager Therapeutics	-$0.41	N/A	N/A	N/A	$6.35 million	N/A
11/2/2026	Q3 2026	DTIL Precision BioSciences	-$0.85	N/A	N/A	N/A	$1.38 million	N/A
8/7/2026	Q2 2026	AGEN Agenus	$0.05	-$0.01	-$0.06	-$0.01	$34.00 million	$34.52 million
8/6/2026	Q2 2026	DTIL Precision BioSciences	-$0.8040	-$1.26	-$0.4560	-$1.26	$0.74 million	N/A
8/6/2026	Q2 2026	VYGR Voyager Therapeutics	-$0.4838	-$0.40	+$0.0838	-$0.40	$4.52 million	$3.17 million
8/3/2026	Q2 2026	CGEN Compugen	-$0.08	-$0.07	+$0.01	-$0.07	$1.29 million	$2.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGEN Agenus	N/A	0.34	0.34
CGEN Compugen	N/A	5.72	5.72
DTIL Precision BioSciences	0.50	12.82	12.82
VYGR Voyager Therapeutics	N/A	7.51	7.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGEN Agenus	61.46%
CGEN Compugen	12.22%
DTIL Precision BioSciences	37.99%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
AGEN Agenus	6.50%
CGEN Compugen	9.50%
DTIL Precision BioSciences	2.70%
VYGR Voyager Therapeutics	12.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGEN Agenus	81	45.16 million	42.23 million	Optionable
CGEN Compugen	75	94.55 million	85.57 million	Optionable
DTIL Precision BioSciences	67	27.60 million	26.86 million	Optionable
VYGR Voyager Therapeutics	141	61.62 million	53.79 million	Optionable

VYGR, CGEN, AGEN, and DTIL Headlines

Recent News About These Companies

Voyager Appoints Robin Swartz As President, CEO Transition Expected In Q1 2027; Stock Down

October 22 at 6:20 PM | rttnews.com

Robin Swartz Appointed President of Voyager Therapeutics with CEO Succession Planned for 2027

October 21 at 7:28 PM | kalkinemedia.comK

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

October 21 at 8:01 AM | globenewswire.com

Voyager Therapeutics (NASDAQ:VYGR) Stock Breaks Below 50 Day Moving Average - Here's Why

October 21 at 3:39 AM | marketbeat.com

HC Wainwright keeps USD 25 target for Voyager Therapeutics stock

October 20 at 1:36 PM | ad-hoc-news.deA

Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average - Here's What Happened

October 13, 2026 | marketbeat.com

Voyager Therapeutics stock gets Wells Fargo Buy rating and USD 10 target

October 6, 2026 | ad-hoc-news.deA

Voyager Therapeutics (NASDAQ:VYGR) Shares Break Below Fifty Day Moving Average - Here's What Happened

September 26, 2026 | marketbeat.com

Why Voyager Therapeutics, Inc.’s (VYGR) Stock Is Down 5.05%

September 24, 2026 | aaii.comA

Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

September 10, 2026 | seekingalpha.com

Voyager to Present at Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

TD Cowen Remains a Buy on Voyager Therapeutics (VYGR)

August 24, 2026 | theglobeandmail.com

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Voyager Reports Second Quarter 2026 Financial and Operating Results

August 6, 2026 | finance.yahoo.com

Voyager Therapeutics: Q2 Earnings Snapshot

August 6, 2026 | khou.comK

Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst

August 4, 2026 | theglobeandmail.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026 | markets.businessinsider.com

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026

July 13, 2026 | globenewswire.com

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

July 2, 2026 | aol.comA

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make Money

July 2, 2026 | 247wallst.com

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

June 30, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VYGR, CGEN, AGEN, and DTIL Company Descriptions

Agenus NASDAQ:AGEN

$6.51 +0.11 (+1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$6.48 -0.03 (-0.48%)

As of 07:50 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Compugen NASDAQ:CGEN

$1.96 -0.16 (-7.55%)

Closing price 04:00 PM Eastern

Extended Trading

$1.97 +0.01 (+0.51%)

As of 07:33 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Precision BioSciences NASDAQ:DTIL

$6.78 +0.07 (+1.04%)

Closing price 04:00 PM Eastern

Extended Trading

$6.76 -0.02 (-0.22%)

As of 07:30 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Voyager Therapeutics NASDAQ:VYGR

$1.86 -0.16 (-7.92%)

Closing price 04:00 PM Eastern

Extended Trading

$1.90 +0.03 (+1.88%)

As of 07:54 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYGR, CGEN, AGEN, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYGR, CGEN, AGEN, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYGR, CGEN, AGEN, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VYGR, CGEN, AGEN, and DTIL Company Descriptions

Agenus NASDAQ:AGEN

Compugen NASDAQ:CGEN

Precision BioSciences NASDAQ:DTIL

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VYGR, CGEN, AGEN, and DTIL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VYGR, CGEN, AGEN, and DTIL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VYGR, CGEN, AGEN, and DTIL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VYGR, CGEN, AGEN, and DTIL Company Descriptions

Agenus NASDAQ:AGEN

Compugen NASDAQ:CGEN

Precision BioSciences NASDAQ:DTIL

Voyager Therapeutics NASDAQ:VYGR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools